TO THE QUESTION OF EFFICACY AND SAFETY OF FORTELYZIN® THERAPY ON ACUTE CORONARY SYNDROME: TWO CLINICAL CASES
https://doi.org/10.38109/2225-1685-2018-1-82-89
Abstract
The article presents two clinical cases of successful reuse thrombolytic drug Fortelyzin® in the total dose of 25-30 mg observed by the authors in patients with acute coronary syndrome with ST-segment elevation, treated in the urgent cardiology department of the State budget institution of Ryazan region «Regional clinical hospital». Patients belonged to different gender and age groups and had various short term forecast on the scale TIMI or GRACE, different duration of ischemic damage of the myocardium until reperfusion. The above observations confirm the high safety and efficiency of Fortelyzin® in acute coronary syndrome.
About the Authors
D. S. Yunevich
The state budget institution of Ryazan region «Regional clinical hospital»
Russian Federation
Russian Federation
PhD in Medicine, cardiologist, anesthesiologist, expert in resuscitation at the urgent cardiology department
Ryazan, Internatsionalnaya str., 3a, 390039
tel: +7-491-236-8040
S. B. Aksentiev
The state budget institution of Ryazan region «Regional clinical hospital»
Russian Federation
Russian Federation
PhD in Medicine, the head of the urgent cardiology department, cardiologist, anesthesiologist, expert in resuscitation
Ryazan, Internatsionalnaya str., 3a, 390039,
tel: +7-491-236-02-34
References
1. Clinical guidelines. Diagnosis and management of ST-segment elevation myocardial infarction. Kardiologicheskij Vestnik. 2014; 4: 5-60 [in Russian].
2. The Vital and Essential Drugs list for 2016: the decree of the Government of the Russian Federation from 26.12.2015 № 2724-p. Sobraniye zakonodatelstva Rossiyskoj Federacii. 2016; 2: 413 [in Russian].
3. Markin S.S., Semenov A.M., Markov V.A. et al. The trial of new made in Russia Thrombolytic Fortelyzin® in patients with acute myocardial infarction. Sibirskij Medicinskij Zurnal. 2012; 27 (1): 27-32 [in Russian].
4. Markov V.A., Duplyakov D.V., Konstantinov S.L. et al. Fortelyzin® versus Metalyse® in ST-segment elevation myocardial infarction: results of multicenter randomized trial FRIDOM 1. Kardiologicheskij Vestnik. 2017; 3: 52-59 [in Russian].
5. Raposeiras-Roubin S., Abu-Assi E., Cabanas-Grandio P., et al. Walking beyond the GRACE (Global Registry of Acute Coronary Events) model in the death risk stratification during hospitalization in patients with acute coronary syndrome: what do the AR-G (ACTION [Acute Coronary Treatment and Intervention Outcomes Network] Registry and GWTG [Get With the Guidelines] Database), NCDR (National Cardiovascular Data Registry), and EuroHeart Risk Scores Provide? JACC Cardiovasc Interv. 2012; 5 (11): 1117-1125.
6. Brilakis, E.S., Mavrogiorgos N.C., Kopecky S.L., et al. Validation of the TIMI risk score for ST-elevation acute myocardial infarction in a community-based coronary care unit registry. Circulation. 2001; 104 (suppl. II): 380.
7. The order of rendering of medical aid to patients with cardiovascular disease: order of Ministry of health of Russia 15.11.2012 № 918н [Electronic resource] // URL: https://www.rosminzdrav.ru/documents/9130-prikaz-ministerstva-zdravoohraneniyarossiyskoy-federatsii-ot-15-noyabrya-2012-g-918n-obutverzhdenii-poryadka-okazaniya-meditsinskoy-pomoschibolnym-s-serdechno-sosudistymi-zabolevaniyami (Date of access 11.12.2017) [in Russian].
Review
For citations:
Yunevich D.S., Aksentiev S.B. TO THE QUESTION OF EFFICACY AND SAFETY OF FORTELYZIN® THERAPY ON ACUTE CORONARY SYNDROME: TWO CLINICAL CASES. Eurasian heart journal. 2018;(1):82-89. https://doi.org/10.38109/2225-1685-2018-1-82-89
Views:
335
Email this article 
